Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STORM: Sintilimab + Docetaxel in Advanced NSCLC
NCT04144582Phase 2Completed
- Sponsor
- Yongchang Zhang
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Yongchang Zhang. Started Jan 2019; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04144582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144582.